JPRN-jRCT2031220534招募中3 期
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO - Tranquillo
Kawai Norisuke0 个研究点目标入组 600 人开始时间: 2022年12月23日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 12age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Inclusion Criteria:
- •1.Participants >=18 years of age, inclusive. Adolescents (12 to <18 years of age) are also eligible for this study, but only if approved by the local IRB/EC and regulatory health authority. Where these approvals have not been granted, only participants >=18 years of age will be enrolled. Adolescent participants will not be enrolled in the United States.
- •Disease Characteristics:
- •2.Eligible participants must have at both Screening and Baseline:
- •*A clinical diagnosis of non segmental vitiligo for at least 3 months; and
- •*BSA involvement 4%-60% inclusive, excluding involvements at palms of the hands, dorsal aspect of fingers and thumbs including metacarpophalangeal joints, soles of the feet, or dorsal aspect of the feet; and
- •*BSA >=0.5% involvement on the face (face is defined as including the area on the forehead to the original hairline, on the check to the jawline vertically to the jawline, and laterally from the corner of the mouth to the tragus. The face will not include scalp, ears, neck, or surface area of the lips, but will include the nose and the eyelids; and
- •*F-VASI >=0.5 & T-VASI >=3; and
- •*Either active or stable disease non segmental vitiligo at both Screening and Baseline visits. All participants who do not have the features of active vitiligo (defined below) are required to have stable disease.
- •Active vitiligo is defined as:
- •*Participants will be classified as having active vitiligo based on the presence of at least one active lesion at baseline defined as one of the following:
- •*New/extending lesion(s) in the 3 months prior to Screening visit (confirmed by photographs or medical record):
- •*Confetti-like lesion(s);
- •*Trichrome lesion(s);
- •*Koebner phenomenon/phenomena (excluding Type 1 [history based on isomorphic reaction]). The Koebner phenomenon manifests as depigmentation at sites of trauma, usually in a linear arrangement.
- •Stable vitiligo is defined as an absence of signs of active disease. All participants who do not have the features of active vitiligo (defined above) are required to have stable disease.
- •Eligibility is determined at Screening based on the resulting scores from the local in-person reads of F-VASI, T-VASI, and BSA.
- •Other Inclusion Criteria:
- •3.If receiving concomitant medications for any reason other than vitiligo, participant must be on a stable regimen, which is defined as not starting a new drug or changing dosage within 7 days or 5 half-lives (whichever is longer) prior to Day 1. Participant must be willing to stay on a stable regimen during the duration of the study.
- •4.Must agree to stop all other treatments for vitiligo from Screening through the final follow-up visit.
排除标准
- •Exclusion Criteria:
- •1.Any psychiatric condition including recent or active suicidal ideation or behavior that meets any of the following criteria:
- •*Suicidal ideation associated with actual intent and a method or plan in the past year: Yes answers on items 4 or 5 of the C-SSRS administered at the screening visit.
- •*Previous history of suicidal behaviors in the past 5 years: Yes answer (for events that occurred in the past 5 years) to any of the suicidal behavior items of the C-SSRS.
- •*For adults, any lifetime history of serious suicidal behavior or recurrent suicidal behavior. For adolescents, any previous lifetime history of suicidal behavior.
- •2.Medical conditions pertaining to vitiligo and other diseases/conditions affecting the skin:
- •*Participants that have other types of vitiligo that do not meet criteria for active or stable vitiligo as noted in inclusion criterion #2 (including, but not limited to, segmental vitiligo and mixed vitiligo).
- •*Currently have active forms of other hypopigmentation (including but not limited to Vogt-Koyanagi-Harada disease, malignancy-induced hypopigmentation [melanoma and mycosis fungoides], post-inflammatory hypopigmentation, pityriasis alba [minor manifestation of atopic dermatitis], senile leukoderma [age-related depigmentation], chemical/drug-induced leukoderma, ataxia telangiectasia, tuberous sclerosis, melasma, and congenital hypopigmentation disorder including piebaldism, Waardenburg syndrome, hypomelanosis of Ito, incontinentia pigmenti, dyschromatosis symmetrica hereditarian, xeroderma pigmentosum, and nevus depigmentosus). NOTE: Coexistence of halo nevus/nevi (also known as Sutton nevus/nevi) is permitted.
- •*Currently have active forms of inflammatory skin disease(s) or evidence of skin conditions (for example, morphea, discoid lupus, leprosy, syphilis, psoriasis, seborrheic dermatitis) at the time of the Screening or Baseline Visit that in the opinion of the investigator would interfere with evaluation of vitiligo or response to treatment.
- •*Leukotrichia in more than 33% of the face surface area affected with vitiligo lesions OR leukotrichia in more than 33% of the total body surface area affected with vitiligo lesions.
- •*Have active acute or chronic skin infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to first dose on Day 1, or superficial skin infections within 2 weeks prior to first dose on Day 1. NOTE: participants may be rescreened after the infection resolves.
- •3.General Infection History:
- •*Having a history of systemic infection requiring hospitalization, parenteral antimicrobial, antiviral (including biologic treatment), antiparasitic, antiprotozoal, or antifungal therapy, or as otherwise judged clinically significant by the investigator within 6 months prior to Day 1.
- •*Have active acute or chronic infection requiring treatment with oral antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to Day 1 or superficial skin infections within 2 weeks prior to first dose on Day 1. NOTE: participants may be rescreened after the infection resolves.
- •*Evidence or history of untreated, currently treated or inadequately treated active or latent infection with Mycobacterium TB
- •4.Specific Viral Infection History:
- •*History (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent (more than one episode of) localized, dermatomal herpes zoster.
研究者
相似试验
已完成
不适用
A PHASE III, 52 WEEK, RANDOMIZED, DOUBLE-BLIND, 3-ARM PARALLEL GROUP STUDY, COMPARING THE EFFICACY, SAFETY AND TOLERABILITY OF THE FIXED DOSE TRIPLE COMBINATION FF/UMEC/VI WITH THE FIXED DOSE DUAL COMBINATIONS OF FF/VI AND UMEC/VI, ALL ADMINISTERED ONCE-DAILY IN THE MORNING VIA A DRY POWDER INHALER IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE-J44 Other chronic obstructive pulmonary diseaseOther chronic obstructive pulmonary diseaseJ44PER-042-14GlaxoSmithKline,189
进行中（未招募）
1 期
A phase 3 study investigating the efficacy, safety and tolerability of PF-04950615 in patients with elevated levels of cholesterol in the blood caused by a defective geneMedDRA version: 18.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861Heterozygous Familial HypercholesterolemiaEUCTR2013-002644-87-NLPfizer Inc., 235 East 42nd Street, New York, NY 10017300
进行中（未招募）
1 期
This study is a multicenter, randomized study in subjects with high cholesterol receiving highly effective statins to assess the efficacy, safety and tolerability of RN316 (PF-04950615) to lower LDL-C.MedDRA version: 18.0Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 100000004861Primary Hyperlipidemia or mixed DyslipidemiaMedDRA version: 18.0Level: LLTClassification code 10020667Term: HyperlipidemiaSystem Organ Class: 100000004861EUCTR2014-000478-20-NLPfizer Inc., 235 East 42nd Street, New York, ny 10017690
进行中（未招募）
1 期
This study is a multicenter, randomized study in subjects with high cholesterol receiving highly effective statins to assess the efficacy, safety and tolerability of RN316 (PF-04950615) to lower LDL-C.Primary Hyperlipidemia or mixed DyslipidemiaMedDRA version: 18.1Level: LLTClassification code 10020667Term: HyperlipidemiaSystem Organ Class: 100000004861MedDRA version: 18.1Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 100000004861EUCTR2014-000478-20-GBPfizer Inc., 235 East 42nd Street, New York, ny 10017690
进行中（未招募）
1 期
This study is a multicenter, randomized study in subjects with high cholesterol receiving highly effective statins to assess the efficacy, safety and tolerability of RN316 (PF-04950615) to lower LDL-C.Primary Hyperlipidemia or mixed DyslipidemiaMedDRA version: 19.0Level: LLTClassification code 10020667Term: HyperlipidemiaSystem Organ Class: 100000004861MedDRA version: 19.0Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 100000004861EUCTR2014-000478-20-CZPfizer Inc., 235 East 42nd Street, New York, ny 10017690